new_0222_0301|OLMA|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0301|OLMA|Long Name|1|1|Olema Pharmaceuticals inc Total Current Assets (Quarterly) (USD)|Olema Pharmaceuticals inc Cash and Short Term Investments (Quarterly) (USD)|Olema Pharmaceuticals inc Inventories (Quarterly) (USD)|Olema Pharmaceuticals inc Net PP&E (Quarterly) (USD)|Olema Pharmaceuticals inc Goodwill and Intangibles (Quarterly) (USD)|Olema Pharmaceuticals inc Total Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Current Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Long Term Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Deposits (Quarterly) (USD)|Olema Pharmaceuticals inc Book Value (Quarterly) (USD)|Olema Pharmaceuticals inc Retained Earnings (Quarterly) (USD)|Olema Pharmaceuticals inc Treasury Stock (Quarterly) (USD)|Olema Pharmaceuticals inc EV to Revenues|Olema Pharmaceuticals inc EV to Earnings|Olema Pharmaceuticals inc EV to Free Cash Flow|Olema Pharmaceuticals inc EV to Assets (Quarterly)|Olema Pharmaceuticals inc PS Ratio|Olema Pharmaceuticals inc PE Ratio|Olema Pharmaceuticals inc Price to Book Value|Olema Pharmaceuticals inc PEG Ratio|Olema Pharmaceuticals inc Debt to Equity Ratio|Olema Pharmaceuticals inc Dividend Yield|Olema Pharmaceuticals inc Shareholder Yield (TTM)|Olema Pharmaceuticals inc Percent of Shares Outstanding Short|Olema Pharmaceuticals inc Total Receivables (Quarterly) (USD)|Olema Pharmaceuticals inc Total Payables (Quarterly) (USD)|Olema Pharmaceuticals inc Total Capital Stock (Quarterly) (USD)|Olema Pharmaceuticals inc Return on Invested Capital|Olema Pharmaceuticals inc Quality Ratio Score|Olema Pharmaceuticals inc Momentum Score|Olema Pharmaceuticals inc Beta (1Y)|Olema Pharmaceuticals inc Sustainable Growth Rate (TTM)|Olema Pharmaceuticals inc Institutional Investor Ownership Percentage|Olema Pharmaceuticals inc Average Diluted Shares Outstanding (Quarterly)|Olema Pharmaceuticals inc Total Employees (Annual)|Olema Pharmaceuticals inc EPS Diluted (Quarterly) (USD)|Olema Pharmaceuticals inc SG&A Expense (Quarterly) (USD)|Olema Pharmaceuticals inc Shares Outstanding|Olema Pharmaceuticals inc Repurchase of Capital Stock (Quarterly) (USD)|Olema Pharmaceuticals inc Ordinary Shares Number (Quarterly)|Olema Pharmaceuticals inc Payout Ratio|Olema Pharmaceuticals inc Quick Ratio (Quarterly)|Olema Pharmaceuticals inc Normalized Diluted EPS (Quarterly) (USD)|Olema Pharmaceuticals inc Stock Buybacks (Quarterly) (USD)|Olema Pharmaceuticals inc Effective Tax Rate (TTM)|Olema Pharmaceuticals inc Return on Equity|Olema Pharmaceuticals inc Net Income (TTM) (USD)|Olema Pharmaceuticals inc Revenue (TTM) (USD)|Olema Pharmaceuticals inc Dividend Per Share (Quarterly) (USD)|Olema Pharmaceuticals inc Revenue (Quarterly) (USD)|Olema Pharmaceuticals inc Gross Profit (Quarterly) (USD)|Olema Pharmaceuticals inc Pre-Tax Income (Quarterly) (USD)|Olema Pharmaceuticals inc Net Income (Quarterly) (USD)|Olema Pharmaceuticals inc Net Interest Income (Quarterly) (USD)|Olema Pharmaceuticals inc Price (USD)|Olema Pharmaceuticals inc Total Return Price (USD)|Olema Pharmaceuticals inc Enterprise Value (USD)|Olema Pharmaceuticals inc 30-Day Average Daily Volume|Olema Pharmaceuticals inc 1 Year Price Returns (Daily)|Olema Pharmaceuticals inc Short Interest|Olema Pharmaceuticals inc PE Ratio (Forward)|Olema Pharmaceuticals inc PE Ratio (Forward 1y)|Olema Pharmaceuticals inc PS Ratio (Forward)|Olema Pharmaceuticals inc PS Ratio (Forward 1y)|Olema Pharmaceuticals inc Quarterly EPS Estimates (USD)|Olema Pharmaceuticals inc Quarterly Revenue Estimates (USD)|Olema Pharmaceuticals inc Quarterly EPS Surprise|Olema Pharmaceuticals inc Quarterly Revenue Surprise|Olema Pharmaceuticals inc Quarterly Actual EPS (USD)|Olema Pharmaceuticals inc Quarterly Actual Revenue (USD)|Olema Pharmaceuticals inc Revenue Estimates for Current Fiscal Year (USD)|Olema Pharmaceuticals inc Revenue Estimates for Next Fiscal Year (USD)|Olema Pharmaceuticals inc Price Target (USD)|Olema Pharmaceuticals inc Consensus Recommendation|Olema Pharmaceuticals inc Price Target Num Estimates|Olema Pharmaceuticals inc EPS Estimates for Current Fiscal Year (USD)|Olema Pharmaceuticals inc EPS Estimates for Next Fiscal Year (USD)|Olema Pharmaceuticals inc Research and Development Expense (Quarterly) (USD)|Olema Pharmaceuticals inc Reconciled Depreciation (Quarterly) (USD)|Olema Pharmaceuticals inc Non-Operating Interest Expense (Quarterly) (USD)|Olema Pharmaceuticals inc Land and Improvements (Quarterly) (USD)|Olema Pharmaceuticals inc Buildings and Improvements (Quarterly) (USD)|Olema Pharmaceuticals inc Other Properties (Quarterly) (USD)|Olema Pharmaceuticals inc Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0301|OLMA|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0301|OLMA||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0301|OLMA||5|5|127.8|127.8|0|127.8|0|127.8|127.8|127.8|0|127.8|127.8|0|0|0|1.44755244755|0|0|0|1.45222929936|0|0|1.45222929936|0|15.25|0|127.8|127.8|0|0|31|31|0|0|91.2857142857|45|91.2857142857|91.2857142857|32.1818181818|91.25|127.8|0|0|91.2857142857|0|0|0|91.25|0|0|0|0|91.2857142857|91.2857142857|91.2857142857|1.45222929936|1.45222929936|1.45222929936|1.43859649123|1.46774193548|15.25|0|0|0|0|91.25|91.25|91|0|91|91|33.1818181818|40.5555555556|22.8125|10.6486486486|22.8125|21.0588235294|23.8666666667|91.2857142857|91.2857142857|91.2857142857|0|0|91.25|91.25
new_0222_0301|OLMA||6|6|5|5|0|5|0|5|5|5|0|5|5|0|0|0|286|0|0|0|314|0|0|314|0|28|0|5|5|0|0|1|2|0|0|7|1|7|7|11|4|5|0|0|7|0|0|0|4|0|0|0|0|7|7|7|314|314|314|285|62|28|0|0|0|0|8|8|3|0|3|3|11|9|16|37|16|17|15|7|7|7|0|0|4|4
new_0222_0301|OLMA||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0301|OLMA|201912|201912|201912|0.103|0.068||0.026||10.726|1.378|9.348||-10.594|-10.762|||||||||||||||0.935|0|||||||14.0986||-0.0721|0.107|||37.5197|||-0.0721|||||||||-1.017|-1.017|0||||||||||||||||||||||||0.91|0.003|0||||
new_0222_0301|OLMA|202003|202003|202003||||||||||||||||||||||||||||||||||14.0986||-0.1201|0.248||||||-0.1201|||||||||-1.693|-1.693|-0.65||||||||||||||||||||||||0.795|0.003|0.653||||
new_0222_0301|OLMA|202006|202006|202006||||||||||||||||||||||||||||||||||14.0986||-0.174|0.539||||||-0.174|||||||||-2.453|-2.453|0.033||||||||||||||||||||||||1.947|0.002|0||||
new_0222_0301|OLMA|202009|202009|202009|129.087|127.824||0.024||5.273|5.273|0||125.41|-22.963|||||||||||||||0.097|0.003|||||||37.5197||-0.2589|3.195||-2.289|39.3082|||-0.2091||||-13.007|||||-7.844|-7.844|0.023||||||||||||||||||||||||4.673|0.002|0|||0.088|0.023
new_0222_0301|OLMA|202011|202009|202009|||||||||||||||||||16.3357|||0||1.0918|||||||||25.7919||22|||40.1697|||||||||||||||||51|51|1920.8307|||438563||||||||||||||||||||||||
new_0222_0301|OLMA|202012|202012|202012|342.137|338.549||0.075||4.585|4.585|0||338.137|-33.094||||-77.8732||||5.5893|||0||1.8086||1.361|0.003|||||||39.3082|37|-0.5|3.842|39.3082|0|39.3082|||-0.5||||-22.121|||||-10.131|-10.131|0.001|48.08|48.08|1551.3893|||710914|||||-0.155|0|-222.5806||-0.5|0|0|0|60.6667|1.25|3|-1.161|-1.2059|6.289|0.004|0||||
new_0222_0301|OLMA|202101|202012|202012|||||||||||||||-66.7646||||4.9348|||0||1.1891|||||||||||||||||||||||||||||||42.45|42.45|1330.0841|87569.1333||467424||||||||||||||1.25||||||||||
new_0222_0301|OLMA|202102|202012|202012|||||||||||||||-61.7726||||4.6407|||0||1.1786|||||||||||||||||||||||||||||||39.92|39.92|1230.6343|92300.3333||463282||||||||||||||1.25||||||||||
new_0222_0301|OLMA|202103|202103|202103|330.265|326.968||0.526||5.277|5.277|0||326.024|-48.433||||-34.3521||||4.0881|||0||2.1434||0.49|0.003|||||||39.3258||-0.39|4.758|40.1697||40.1697|||-0.39||||-35.767|||||-15.339|-15.339|0.111|33.18|33.18|1005.8626|226091.9||860988|||||-0.2668|0|-46.1495||-0.39|0|||61.6667|1.25|3|-1.2142|-2.11|10.692|0.009|0|||0.537|0.059
new_0222_0301|OLMA|202104|202103|202103|||||||||||||||-27.3144||||3.4561|||0||3.3182||||||||||||||40.1697|||||||||||||||||28.05|28.05|799.7921|216664.4||1332920||||||||||||||1.25||||||||||
new_0222_0301|OLMA|202105|202103|202103|||||||||||||||-27.1909||||3.445|||0||4.7999||||||||||||||40.1697|||||||||||||||||27.96|27.96|796.1768|174831.6||1928101|||||||||||0|0|54.3333|1.25|3|-1.676|-2.596|||||||
new_0222_0301|OLMA|202106|202106|202106|320.854|318.144||0.866||8.146|8.146|0||314.084|-64.839||||-21.107||||3.5235|||0||5.7068||0.452|0.003|||||||39.4153||-0.42|4.612|39.5526||39.5526|||-0.42||||-49.72|||||-16.406|-16.406|0.117|27.98|27.98|788.5377|280866.2667||2257189|||||-0.3831|0|-9.6262||-0.42|0|0|0|55.75|1.2|4|-1.704|-2.734|11.91|0.031|0|||0.909|0.059
new_0222_0301|OLMA|202107|202106|202106|||||||||||||||-16.3428||||2.9568|||0||6.0937|||||||||||||||||||||||||||||||23.48|23.48|610.551|244184.3333||2410217|||||||||||0||55.75|1.2|4|||||||||
new_0222_0301|OLMA|202108|202106|202106|||||||||||||||-23.1651||||3.7683|||0||5.2178||||||||||||||39.5578|||||||||||||||||29.92|29.92|865.4254|265683.1||2064038|||||||||||0|0|56|1.2|4|-1.6918|-2.4952|||||||
new_0222_0301|OLMA|202109|202109|202109|308.28|305.954||0.975||8.901|8.901|0||300.894|-82.552||||-18.7418||||3.6346|||0||6.0811||0.373|0.003|||||||39.6077||-0.45|5.239|39.6813|0|39.6813|||-0.45||||-59.589|||||-17.713|-17.713|0.105|27.56|27.56|787.6626|364130.2667||2413054|||||-0.4309|0|-4.4447||-0.45|0||0||1.2||-1.6168|-2.3085|12.523|0.05|0|||1.067|0.059
new_0222_0301|OLMA|202110|202109|202109|||||||||||||||-18.2131||||3.5607|||0||6.7981|||||||||||||||||||||||||||||||27|27|765.4411|338222||2697585|||||||||||0|0|55.75|1.2|4|-1.6182|-2.3242|||||||
new_0222_0301|OLMA|202111|202109|202109|||||||||||||||-1.1079||||1.1716|||0||10.0905|||||||1.7402|||||||40.2876|||||||||||||||||8.75|8.75|46.5625|868674|-82.8431|4065217|||||||||||0|0|55.5|1.2|4|-1.7125|-2.4867|||||||
new_0222_0301|OLMA|202112|202112|202112|||||||||||||||-1.6927||||1.2532|||0||9.5204||||||1|1.9879||||||||||||||||||||||||9.36|9.36|71.1379|1317534.5667|-80.5324|3835551|||||-0.4625|0|||||0|0|46.25|1.2|4|-1.7125|-2.4867|||||||
new_0222_0301|OLMA|202201|202112|202112|||||||||||||||1.1161||||0.8609|||0||6.4886||||||1|2.4005||||||||||||||||||||||||6.43|6.43|-46.9047|451306.5667|-84.8528|2614116||||||||||||||1.2||||||||||
new_0222_0301|OLMA|202202|202112|202112|||||||||||||||2.9662||||0.6025|||0|||||||||||||||||||||||||||||||||4.5|4.5|-124.6598|448248.3667|-91.018|||||||||||||||||||||||||
new_0222_0301|OLMA|202203|202203|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.56|0||||||||||||||||||
new_0222_0301|OLMA|202206|202206|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.615|0||||||||||||||||||
new_0222_0301|OLMA|202209|202209|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.675|0||||||||||||||||||
new_0222_0301|OLMA|202212|202212|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.805|0||||||||||||||||||